Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Central Pacific Bank Trust Division

Central Pacific Bank Trust Division cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 24.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,702 shares of the company’s stock after selling 1,200 shares during the period. Central Pacific Bank Trust Division’s holdings in Neurocrine Biosciences were worth $505,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in NBIX. Ashton Thomas Private Wealth LLC purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $28,000. Blue Trust Inc. increased its stake in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares in the last quarter. Plato Investment Management Ltd raised its holdings in shares of Neurocrine Biosciences by 44.1% in the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after buying an additional 130 shares during the last quarter. Truvestments Capital LLC acquired a new stake in shares of Neurocrine Biosciences during the third quarter worth $63,000. Finally, True Wealth Design LLC increased its position in shares of Neurocrine Biosciences by 11,740.0% in the 3rd quarter. True Wealth Design LLC now owns 592 shares of the company’s stock valued at $68,000 after acquiring an additional 587 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

NBIX has been the topic of several research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Raymond James reiterated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. BMO Capital Markets dropped their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a report on Thursday, October 17th. Finally, Royal Bank of Canada reduced their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $166.29.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $138.10 on Friday. The stock has a market capitalization of $13.98 billion, a PE ratio of 37.02 and a beta of 0.33. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The company has a fifty day moving average of $128.11 and a two-hundred day moving average of $130.81.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 272 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the transaction, the insider now owns 2,507 shares of the company’s stock, valued at $346,216.70. This represents a 9.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the transaction, the insider now owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,694 shares of company stock worth $479,230 in the last 90 days. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.